EcoDrugPlus

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSXMAG00000004019
Gene Symbol: GSK3B
3 Cross references
222 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSXMAG00000016562
Gene Symbol: LOC102236245
3 Cross references
187 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSXMAG00000004972
Gene Symbol: LOC106700302
2 Cross references
155 Possible Orthologues:

Granzyme G-Like

Ensembl ID : ENSXMAG00000012368
Gene Symbol: LOC102230245
2 Cross references
963 Possible Orthologues:

Granzyme-Like Protein 1

Ensembl ID : ENSXMAG00000012363
Gene Symbol: LOC102229982
2 Cross references
967 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSXMAG00000013222
Gene Symbol: GHRHR
4 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSXMAG00000009156
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSXMAG00000005656
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSXMAG00000018053
Gene Symbol: GUCY1A2
4 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSXMAG00000005668
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha

Ensembl ID : ENSXMAG00000008303
Gene Symbol: LOC102218115
3 Cross references
345 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha 1

Ensembl ID : ENSXMAG00000008315
Gene Symbol: LOC102218377
3 Cross references
330 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).